I'm going to change my guess range here.
Based on approval decision being in 5 weeks - and no safety or efficacy or manufacturing issues observed.
Even if FDA issue CRL #2, it will be minor enough based on the prevous complete review letter, that any further resubmission and review will be completed before 12 months in my opinion.
Based on that I think $1.50 to $4 with any likely takeover significantly north of that.
Easy money post approval for big pharma.
If they could get 30% market penetration as safest, best in class front line treatment.
4.6 Billion in sales at $350 a unit annually.... easily for them justifies paying the premium up front much greater.
Can't wait for approval, and then to see the product rip through market pentration. Like a sonic boom
Where will we be in 12 months time?, page-39
-
- There are more pages in this discussion • 217 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.0¢ | $1.603M | 4.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 378157 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 98000 | 5 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |